Radiotracers for Imaging Cannabinoid Sub-Type1 (CB1) Receptor
Posted Jun 15 2010 5:00pm
Description of Invention: The present invention relates to novel radiolabeled compounds for imaging cannabinoid sub-type 1 (CB1) receptors in brains of mammals, particularly humans, using positron emission tomography (PET) or single photon emission computed tomography (SPECT). These radioligands can be used in clinical research, diagnostics, or drug discovery and development, in that, they permit understanding of the role of CB1 receptors in neuropsychiatric disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, multiple sclerosis, depression, mood disorder, anxiety, schizophrenia, drug addiction, alcohol disorder, obesity and anorexia.
In vivo imaging of CB1 receptor in mammals, particularly humans
Diagnostic imaging of CB1 receptors in subjects having a neurological, neuropsychiatric, neurodegenerative or other condition and treatment
Advantages: The principal radioligand under the claim is effective for imaging CB1 receptors in vivo with PET.
Development Status: Primary radioligand has been evaluated in non-human primates with PET.
Patent Status: HHS, Reference No. E-155-2008/1 PCT, Application No. PCT/US2009/043491 filed 11 May 2009 , which published as WO 2009/140210 on 19 Nov 2009
SR Donohue, C Halldin, VW Pike. Synthesis and structure–activity relationships (SARs) of 1,5-diarylpyrazole cannabinoid type-1 (CB1) receptor ligands for potential use in molecular imaging. Bioorg Med Chem. 2006 Jun 1;14(11):3712-3720. [ PubMed: 16466922 ]
SR Donohue, VW Pike, SJ Finnema, P Truong, J Andersson, B Gulyás, C Halldin. Discovery and labeling of high affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors. J Med Chem. 2008 Sep 25;51(18):5608-5616. [ PubMed: 18754613 ]
Licensing Status: Available for licensing.
Portfolios: Devices/Instrumentation Devices/Instrumentation - Diagnostics Central Nervous System Central Nervous System - Research Materials In-vivo Data
For Additional Information Please Contact: Susan Ano Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5515 Fax: 301-402-0220